UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
------------
FORM 6-K
------------
REPORT OF FOREIGN ISSUER
Pursuant to Rule 13a-16 or 15d-16
of the Securities Exchange Act of 1934
June 20 2007
------------
NOVO NORDISK A/S
(Exact name of Registrant as specified in its charter)
NOVO ALLE
DK-2880, BAGSVAERD
DENMARK
(Address of principal executive offices)
------------
Indicate by check mark whether the registrant files or will file annual reports
under cover of Form 20-F or Form 40-F
Form 20-F [X] Form 40-F [ ]
Indicate by check mark whether the registrant by furnishing the information
contained in this Form is also thereby furnishing the information to the
Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.
Yes [ ] No [X]
If "Yes" is marked, indicate below the file number assigned to the registrant in
connection with Rule 12g-32(b):82-_____________________
TRANSACTION IN OWN SHARES
REDUCTION OF THE SHARE CAPITAL AND HOLDING OF OWN SHARES (19 JUNE 2007)
At Novo Nordisk's ordinary general meeting on the 7 March 2007 it was decided to
reduce the company's B-share capital from DKK 566,432,800 to DKK 539,472,800 by
cancellation of part of the company's portfolio of own B shares at a nominal
value of DKK 26,960,000 divided into 13,480,000 B shares of DKK 2 each.
Today, Novo Nordisk has registered the final implementation of the reduction of
the share capital with the Danish Commerce and Companies Agency and cancelled
nominally DKK 26,960,000 B shares. After the reduction of the share capital, the
company's share capital is nominally DKK 646,960,000, which is divided into an A
share capital of nominally DKK 107,487,200 and a B share capital of nominally
DKK 539,472,800.
HOLDING OF OWN SHARES
In the company's stock exchange announcement no 8/2007 of 3 April 2007 it was
stated that Novo Nordisk A/S (NYSE: NVO) and its wholly-owned affiliates as per
31 March 2007 owned 19,163,309 of its own B shares of DKK 2, corresponding to a
total nominal value of DKK 38,326,618 or 5.69% of the total share capital.
Since 3 April 2007 a total of 138,000 B shares have been repurchased by Novo
Nordisk A/S, and 306,625 B shares have been disposed of to employees who have
exercised options granted by Novo Nordisk.
Following the cancellation of nominally DKK 26,960,000 (13,480,000 shares) of
the company's own B shares and pursuant to Section 28 of the Danish securities
Trading Act, it is hereby announced that Novo Nordisk A/S and its wholly-owned
affiliates as per 19 June 2007 own 5,514,684 of its own B shares. This
corresponds to a total nominal value of DKK 11,029,368 B-shares or 1.7% of the
total share capital.
Novo Nordisk is a healthcare company and a world leader in diabetes care. The
company has the broadest diabetes product portfolio in the industry, including
the most advanced products within the area of insulin delivery systems. In
addition, Novo Nordisk has a leading position within areas such as haemostasis
management, growth hormone therapy and hormone replacement therapy. Novo Nordisk
manufactures and markets pharmaceutical products and services that make a
significant difference to patients, the medical profession and society. With
headquarters in Denmark, Novo Nordisk employs approximately 23.600 full-time
employees in 79 countries, and markets its products in 179 countries. Novo
Nordisk's B shares are listed on the stock exchanges in Copenhagen and London.
Its ADRs are listed on the New York Stock Exchange under the symbol 'NVO'. For
more information, visit novonordisk.com.
Further information:
Media: Investors:
Outside North America: Outside North America:
Elin K Hansen Mads Veggerby Lausten
Tel: (+45) 4442 3450 Tel: (+45) 4443 7919
ekh@novonordisk.com mlau@novonordisk.com
Hans Rommer
Tel: (+45) 4442 4765
hrmm@novonordisk.com
In North America: In North America:
Lori Moore Christian Qvist Frandsen
Tel: (+1) 609 919 7991 Tel: (+1) 609 919 7937
lrmo@novonordisk.com cqfr@novonordisk.com
Stock Exchange Announcement no 16 / 2007
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the
Registrant has duly caused this report to be signed on its behalf of the
undersigned, thereunto duly authorized.
Date: June 20 2007 NOVO NORDISK A/S
---------------------------------------------------
Lars Rebien Sorensen,
President and Chief Executive Officer